ATLAS-1: Longitudinal assessment of treatments for depressed mood
ATLAS-1: Advanced Trial for Longitudinal Assessment in Salma 1
This project will try to use clinical data from adults with depressed mood who receive esketamine, conventional TMS, or SAINT to build tools that predict which treatment is most likely to help.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 5000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Salma Health, Inc. Academic / other |
| Locations | 2 sites (La Jolla, California and 1 other locations) |
| Trial ID | NCT07528014 on ClinicalTrials.gov |
What this trial studies
This observational study collects multimodal clinical data from adults treated for depressed mood in routine care at two Salma Health clinics and may incorporate authorized retrospective data from existing databases. Participants will be those prescribed esketamine, conventional transcranial magnetic stimulation (TMS), or Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT) as part of standard care, with data used to develop and validate predictive models of treatment response. The approach focuses on real-world clinical measurements rather than experimental interventions and emphasizes model training and validation across available datasets. Outcomes will include model performance metrics and the feasibility of integrating such tools to inform treatment selection.
Who should consider this trial
Good fit: Adults aged 18 or older presenting with depressed mood who are prescribed esketamine, conventional TMS, or SAINT and can provide informed consent are ideal candidates.
Not a fit: People who are not receiving those specific treatments, are under 18, or have conditions that prevent safe participation in the study assessments may not benefit from this project.
Why it matters
Potential benefit: If successful, the models could help clinicians choose the most promising treatment sooner, reducing trial-and-error and speeding relief for patients.
How similar studies have performed: Prior research using predictive models for TMS and ketamine-like therapies has shown promise in controlled settings, but these approaches remain experimental and need validation in real-world clinical datasets.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults (≥18 years) of any gender identity presenting for care with a depressed mood. * Prescribed treatment with esketamine, conventional TMS, or SAINT as part of standard clinical care. * Able to provide informed consent and comply with all study requirements. Exclusion Criteria: * Any condition deemed by the investigator to preclude safe participation in study assessments.
Where this trial is running
La Jolla, California and 1 other locations
- Salma Health — La Jolla, California, United States (Recruiting)
- Salma Health — Laguna Hills, California, United States (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.